Tectonic Therapeutic has done well to advance its Fc-fusion protein candidate TX45 into a phase 2 study targeting patients ...
TECX stock reached a new 52-week high this week, with shares trading at an impressive $53.6. According to InvestingPro data, analysts maintain a strong buy consensus with price targets ranging from ...
WATERTOWN, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), today announced that it has entered into a securities purchase agreement for a ...
Tectonic Therapeutic, Inc.'s stock surged 120% on positive Phase 1b data for TX45 in treating PH-HFpEF, offering a potential ...
Tectonic Therapeutic (NASDAQ:TECX – Free Report) had its price objective raised by Wells Fargo & Company from $79.00 to $112.00 in a research report report published on Friday morning,Benzinga reports ...
(RTTNews) - Tectonic Therapeutic Inc. (TECX), a clinical-stage biotechnology company, on Thursday announced positive interim data from its ongoing Phase 1b clinical trial of TX45 in patients with ...
Shares of Tectonic Therapeutic (NASDAQ:TECX) added ~40% in the premarket on Thursday after the cardiac medicines developer ...
Tectonic Therapeutic (NASDAQ:TECX – Get Free Report)’s share price traded up 6.7% on Friday after Wells Fargo & Company raised their price target on the stock from $79.00 to $112.00. Wells Fargo & ...